Therapy tracking gets personal, ResMed AirSense 11 leans on smart coaching

ResMed’s AirSense 11 CPAP platform combines automated pressure adjustment with app-based coaching to make home sleep apnea therapy easier to start and stick with. The connected device is now one of the company’s central hardware pillars alongside its myAir digital ecosystem.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 11:39 AM ET. Details in the imprint.

ResMed’s AirSense 11 CPAP platform is positioned as the company’s current flagship for treating obstructive sleep apnea at home, combining a compact bedside unit with guided onboarding and app-based coaching to lower the barrier for first-time users. The device supports multiple therapy modes, automatic pressure adjustment and Bluetooth connectivity, and is increasingly paired with ResMed’s myAir app to personalize feedback on nightly sleep and mask fit.

What ResMed’s AirSense 11 is built to do

At its core, the AirSense 11 is an auto-adjusting positive airway pressure device designed to keep the upper airway open during sleep by delivering a continuous flow of pressurized air through a mask, with the auto-set algorithm adapting to a patient’s breathing patterns throughout the night. ResMed highlights a touch-screen interface, integrated humidifier and the option to run standard CPAP or AutoSet modes, giving sleep clinicians and durable medical equipment providers flexibility to match therapy settings to individual prescriptions while keeping the hardware footprint relatively small on the nightstand.

Where ResMed tries to differentiate the AirSense 11 from earlier generations is in the digital layer: onboarding and daily engagement are closely tied to the myAir smartphone app, which assigns an easy-to-read score based on hours of use, mask leaks and residual apnea events, and then pushes tailored tips to improve comfort and adherence. According to ResMed, this connected approach, which also feeds encrypted usage data back to clinicians via its AirView cloud platform, is aimed at reducing early drop-off from therapy - a long-standing issue in sleep apnea care - by turning raw compliance metrics into coaching-style insights that patients can act on without waiting for their next office visit.

ResMed positions the AirSense 11 as a central piece of its broader strategy to link hardware, software and cloud services across sleep and respiratory care, alongside its expanding portfolio of masks and digital health tools for clinicians and payers. Shares of ResMed (US7611521078) traded on the NYSE under the ticker RMD and most recently closed at $194.57 on 06/14/2026.

ResMed AirSense 11 in brief: key facts

• Product: AirSense 11
• Manufacturer: ResMed Inc.
• Category: Flagship/Bestseller CPAP device
• Launch date: 2021 (initial market introduction)
• MSRP / Price: Typically around $900-$1,200 for device-only in the US, with actual patient cost depending on insurance coverage
• Availability: Prescribed through sleep clinics and durable medical equipment providers in the US and other markets; not sold direct-to-consumer
• Target audience: Adults diagnosed with obstructive sleep apnea who need home CPAP or auto-adjusting PAP therapy
• Key differentiator / USP: Tight integration with ResMed’s myAir app and AirView cloud platform to support remote monitoring and personalized coaching

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.